ReviewBritish journal of clinical pharmacology2001
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
Review in British journal of clinical pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Sensitivity of cognitive function tests to acute hypoxia in healthy subjects: a systematic literature review.Frontiers in physiology · 2023Pooled it
- The effect of antipsychotic treatment on hormonal, inflammatory, and metabolic biomarkers in healthy volunteers: A systematic review and meta-analysis.Pharmacotherapy · 2022Pooled it
- Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation.PloS one · 2023Trial
- Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.Translational psychiatry · 2022Trial
- Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial.Journal of clinical pharmacology · 2021Trial
- First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel MBritish journal of clinical pharmacology · 2021Trial
- Trial
- Trial
- Amygdala Lesions Reduce Anxiety-like Behavior in a Human Benzodiazepine-Sensitive Approach-Avoidance Conflict Test.Biological psychiatry · 2017Trial
- The effects of ketamine and risperidone on eye movement control in healthy volunteers.Translational psychiatry · 2013Trial
- Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.British journal of clinical pharmacology · 2013Trial
- Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.Psychopharmacology · 2013Trial
- Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.British journal of clinical pharmacology · 2011Trial
- Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.British journal of clinical pharmacology · 2009Trial
- Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression.Frontiers in neuroscience · 2025Article
- The computational pharmacology of oculomotion.Psychopharmacology · 2019Article
- Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.Acta pharmacologica Sinica · 2019Review
- Review of serum prolactin levels as an antipsychotic-response biomarker.Open access journal of translational medicine & research · 2018Article
- Preclinical assessment of CNS drug action using eye movements in mice.The Journal of clinical investigation · 2011Article
- Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Expert opinion on drug discovery · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies of novel antipsychotics in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. A useful biomarker should meet the following requirements: a consistent response across studies and antipsychotics; a clear response of the biomarker to a therapeutic dose; a dose-response relationship; a plausible relationship between biomarker, pharmacology and pathogenesis. In the current review, all individual tests found in studies of neuroleptics in healthy volunteers since 1966 were progressively evaluated for compliance with these requirements. A MedLine search yielded 65 different studies, investigating the effects of 23 different neuroleptics on 101 different (variants of) neuropsychological tests, which could be clustered into seven neuropsychological domains. Subjective and objective measures of alertness, and of visual-visuomotor-auditory and motor skills were most sensitive to antipsychotics, although over half of all the studies failed to show statistically significant differences from placebo. The most consistent effects were observed using prolactin response and saccadic eye movements, where 96% and 83% of all studies resp. showed statistically significant effects. The prolactin inducing dose equivalencies relative to haloperidol of 19 different antipsychotic agents correlated with the lowest recommended daily maintenance dose (r(2) = 0.52). This relationship could reflect the clinical practice of aiming for maximum tolerated levels, or it could represent a common basis behind prolactin release and antipsychotic activity (probably D2-receptor antagonism). The number of tests used in human psychopharmacology appears to be excessive. Future studies should look for the most specific and sensitive test within each of the domains that are most susceptible to neuroleptics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.